Design Therapeutics (DSGN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Design Therapeutics

NasdaqGS•Healthcare•Biotechnology

$15.14+0.11(0.01%)Market closed

Market Cap

$765.07M

P/B

3.8x

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

How this company scores

WeakMetricSide Score: 27/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (0/25).

Profitability0/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 3.8x5y range 0.5x – 3.8x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $765.07M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-78.44M
TTM Op. Income: $-79.36M
Q. Op. Income: $-22.18M
TTM Net Income: $-70.80M
Q. Net Income: $-20.16M
EPS: $-0.32
Shares Out.: $62.51M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-78.44M and TTM operating income of $-79.36M show growth is flowing through to the bottom line. However, net income is negative at $70.80M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -2217700000.0%
Net Margin: -2016500000.0%

Op. margin of -2217700000.0% is down 60800000.0% YoY — costs are rising relative to revenue. Net margin at -2016500000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 3.8x

P/S of 0.0x and P/B of 3.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $215.13M
Cash: $12.91M
Long-Term Debt: N/A
Book Value: $201.86M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-15.52M
TTM Free Cash Flow: $-55.14M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-55.14M on $-15.52M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 9% — a weakening trend.